1. Catalysts Evenamide (Schizophrenia Add-On Therapy): The key growth catalyst for Newron is Evenamide, a novel glutamate-modulating drug in Phase III development for treatment-resistant schizophrenia (TRS).

Nebius Group (NASDAQ: NBIS) is a high-growth AI infrastructure provider with a clear path to profitability and strong competitive advantages. Firm created by Volozh who led Yandex, by carving out the non-Russia operations of Yandex.

UBS; GLOBAL RESEARCH; 18 DEC 2024 Summary We're launching coverage of Palantir shares with a Neutral rating, an $80 price target, 2025/2026 estimates that are well above the Street consensus (+200bps on revs growth) and a very positive view of the fundamentals. We root our views in conversations with 17 large Palantir customers and other checks and offer their unvarnished feedback in this report, which focuses more than we normally would on the core "what exactly does Palantir do?" question, in addition to unpacking the uplift from its Al-Data exposure.